Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Overdose | 14 | 2025 | 89 | 4.350 |
Why?
|
| Opioid-Related Disorders | 22 | 2025 | 233 | 3.990 |
Why?
|
| Rural Population | 19 | 2025 | 171 | 3.430 |
Why?
|
| Drug Users | 9 | 2025 | 30 | 2.590 |
Why?
|
| Analgesics, Opioid | 20 | 2025 | 514 | 2.290 |
Why?
|
| Substance-Related Disorders | 10 | 2025 | 451 | 2.130 |
Why?
|
| Hepatitis C | 6 | 2024 | 184 | 1.900 |
Why?
|
| Naloxone | 7 | 2024 | 72 | 1.780 |
Why?
|
| Substance Abuse, Intravenous | 6 | 2024 | 66 | 1.570 |
Why?
|
| Harm Reduction | 6 | 2024 | 29 | 1.450 |
Why?
|
| Narcotic Antagonists | 4 | 2024 | 170 | 1.360 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 97 | 1.260 |
Why?
|
| HIV Infections | 12 | 2025 | 974 | 1.000 |
Why?
|
| Fentanyl | 4 | 2024 | 87 | 0.980 |
Why?
|
| Illinois | 8 | 2024 | 530 | 0.960 |
Why?
|
| Hepatitis C, Chronic | 3 | 2015 | 96 | 0.940 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2025 | 9 | 0.920 |
Why?
|
| Doxycycline | 1 | 2025 | 37 | 0.910 |
Why?
|
| Pharmacies | 1 | 2024 | 12 | 0.850 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 647 | 0.820 |
Why?
|
| Chromatin | 2 | 2023 | 445 | 0.810 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2025 | 111 | 0.810 |
Why?
|
| Buprenorphine | 3 | 2025 | 52 | 0.800 |
Why?
|
| Social Support | 1 | 2024 | 239 | 0.750 |
Why?
|
| Pandemics | 8 | 2023 | 880 | 0.750 |
Why?
|
| Anti-Bacterial Agents | 2 | 2025 | 848 | 0.730 |
Why?
|
| Medicaid | 1 | 2024 | 260 | 0.700 |
Why?
|
| Actins | 2 | 2023 | 472 | 0.700 |
Why?
|
| Health Services Accessibility | 5 | 2025 | 491 | 0.670 |
Why?
|
| Mentoring | 1 | 2021 | 35 | 0.650 |
Why?
|
| Betacoronavirus | 2 | 2020 | 284 | 0.640 |
Why?
|
| Coinfection | 3 | 2021 | 67 | 0.640 |
Why?
|
| Humans | 58 | 2025 | 95992 | 0.620 |
Why?
|
| Prescription Drug Misuse | 1 | 2020 | 13 | 0.620 |
Why?
|
| Prescriptions | 1 | 2019 | 26 | 0.600 |
Why?
|
| United States | 17 | 2025 | 7785 | 0.590 |
Why?
|
| Heroin | 1 | 2019 | 14 | 0.590 |
Why?
|
| Drug Utilization | 1 | 2019 | 69 | 0.570 |
Why?
|
| Hepacivirus | 2 | 2023 | 137 | 0.570 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 334 | 0.560 |
Why?
|
| Uridine Monophosphate | 2 | 2015 | 4 | 0.550 |
Why?
|
| Methamphetamine | 3 | 2024 | 104 | 0.550 |
Why?
|
| Male | 33 | 2025 | 45792 | 0.540 |
Why?
|
| Cross-Sectional Studies | 9 | 2025 | 1880 | 0.540 |
Why?
|
| Hospital Mortality | 1 | 2020 | 485 | 0.530 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2015 | 60 | 0.530 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 296 | 0.510 |
Why?
|
| Female | 32 | 2025 | 49980 | 0.500 |
Why?
|
| Adult | 27 | 2025 | 28636 | 0.490 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 346 | 0.480 |
Why?
|
| Middle Aged | 25 | 2025 | 28299 | 0.460 |
Why?
|
| Ribavirin | 2 | 2015 | 40 | 0.450 |
Why?
|
| Drug Therapy | 1 | 2015 | 70 | 0.450 |
Why?
|
| Antiviral Agents | 2 | 2015 | 504 | 0.440 |
Why?
|
| Social Stigma | 5 | 2025 | 86 | 0.430 |
Why?
|
| Drug Costs | 2 | 2017 | 67 | 0.430 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 44 | 0.420 |
Why?
|
| Tuberculosis | 2 | 2012 | 125 | 0.410 |
Why?
|
| Opiate Substitution Treatment | 3 | 2025 | 48 | 0.410 |
Why?
|
| Sexual and Gender Minorities | 4 | 2025 | 250 | 0.410 |
Why?
|
| Cell Nucleus | 3 | 2024 | 618 | 0.400 |
Why?
|
| Obesity | 1 | 2020 | 1029 | 0.400 |
Why?
|
| Case Management | 2 | 2024 | 29 | 0.390 |
Why?
|
| Sulfonamides | 1 | 2014 | 337 | 0.360 |
Why?
|
| Cost-Benefit Analysis | 6 | 2021 | 500 | 0.350 |
Why?
|
| Buttocks | 1 | 2009 | 10 | 0.310 |
Why?
|
| Chromoblastomycosis | 1 | 2009 | 3 | 0.310 |
Why?
|
| Ascomycota | 1 | 2009 | 16 | 0.300 |
Why?
|
| Exanthema | 1 | 2009 | 40 | 0.290 |
Why?
|
| Retrospective Studies | 8 | 2021 | 10307 | 0.240 |
Why?
|
| Skin | 1 | 2009 | 604 | 0.240 |
Why?
|
| Qualitative Research | 2 | 2024 | 362 | 0.240 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 492 | 0.230 |
Why?
|
| Case Managers | 1 | 2024 | 3 | 0.220 |
Why?
|
| Heterochromatin | 1 | 2024 | 26 | 0.220 |
Why?
|
| Benzodiazepines | 1 | 2025 | 71 | 0.220 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2024 | 29 | 0.220 |
Why?
|
| Standing Orders | 1 | 2024 | 1 | 0.220 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 64 | 0.220 |
Why?
|
| Social Work | 1 | 2024 | 22 | 0.210 |
Why?
|
| Chicago | 5 | 2020 | 1505 | 0.210 |
Why?
|
| Hepatitis C Antibodies | 1 | 2023 | 8 | 0.210 |
Why?
|
| Lamin Type A | 1 | 2023 | 26 | 0.200 |
Why?
|
| Prevalence | 4 | 2024 | 1355 | 0.200 |
Why?
|
| Attitude | 2 | 2024 | 137 | 0.200 |
Why?
|
| RNA Polymerase II | 1 | 2023 | 62 | 0.200 |
Why?
|
| Risk Factors | 5 | 2024 | 5992 | 0.200 |
Why?
|
| Antifungal Agents | 2 | 2017 | 126 | 0.190 |
Why?
|
| Ethambutol | 2 | 2012 | 6 | 0.190 |
Why?
|
| Isoniazid | 2 | 2012 | 8 | 0.190 |
Why?
|
| Health Policy | 1 | 2024 | 208 | 0.190 |
Why?
|
| DNA Damage | 1 | 2024 | 392 | 0.190 |
Why?
|
| Young Adult | 10 | 2025 | 7034 | 0.190 |
Why?
|
| Social Networking | 2 | 2020 | 85 | 0.180 |
Why?
|
| Sexual Behavior | 1 | 2025 | 334 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2019 | 3115 | 0.170 |
Why?
|
| Aged | 7 | 2024 | 20927 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1096 | 0.170 |
Why?
|
| Rural Health Services | 1 | 2020 | 17 | 0.160 |
Why?
|
| Social Norms | 1 | 2019 | 15 | 0.160 |
Why?
|
| Quality of Life | 2 | 2020 | 1816 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 7224 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 22 | 0.150 |
Why?
|
| Gram-Negative Bacteria | 1 | 2019 | 38 | 0.150 |
Why?
|
| Public Health Practice | 1 | 2019 | 11 | 0.150 |
Why?
|
| Homosexuality, Male | 2 | 2020 | 332 | 0.150 |
Why?
|
| Point-of-Care Systems | 2 | 2021 | 156 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1176 | 0.140 |
Why?
|
| Disease Outbreaks | 1 | 2019 | 157 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2020 | 721 | 0.140 |
Why?
|
| Bacteremia | 1 | 2019 | 108 | 0.140 |
Why?
|
| Cross Infection | 1 | 2019 | 159 | 0.140 |
Why?
|
| Sofosbuvir | 2 | 2015 | 9 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 468 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2020 | 9228 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 422 | 0.130 |
Why?
|
| Public Health | 1 | 2019 | 155 | 0.130 |
Why?
|
| Patient Participation | 1 | 2019 | 241 | 0.130 |
Why?
|
| Directly Observed Therapy | 1 | 2017 | 5 | 0.130 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 7 | 0.130 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 27 | 0.130 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2017 | 52 | 0.130 |
Why?
|
| Meglumine | 1 | 2017 | 38 | 0.130 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 31 | 0.130 |
Why?
|
| Nystatin | 1 | 2017 | 2 | 0.130 |
Why?
|
| Candidiasis, Oral | 1 | 2017 | 4 | 0.130 |
Why?
|
| Gentian Violet | 1 | 2017 | 10 | 0.130 |
Why?
|
| Comorbidity | 1 | 2020 | 1017 | 0.120 |
Why?
|
| Time Factors | 3 | 2015 | 5593 | 0.120 |
Why?
|
| Students, Medical | 1 | 2021 | 455 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2019 | 364 | 0.120 |
Why?
|
| Health Behavior | 1 | 2017 | 191 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 148 | 0.120 |
Why?
|
| AIDS Serodiagnosis | 1 | 2016 | 27 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2024 | 4690 | 0.110 |
Why?
|
| Diagnostic Equipment | 1 | 2015 | 4 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2015 | 91 | 0.110 |
Why?
|
| Uganda | 1 | 2015 | 46 | 0.110 |
Why?
|
| India | 2 | 2012 | 139 | 0.110 |
Why?
|
| Health Facilities | 1 | 2015 | 41 | 0.110 |
Why?
|
| Simeprevir | 1 | 2014 | 4 | 0.110 |
Why?
|
| Age Factors | 1 | 2019 | 1959 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 123 | 0.100 |
Why?
|
| Methadone | 2 | 2025 | 51 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 180 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2015 | 171 | 0.100 |
Why?
|
| Incidence | 3 | 2013 | 1723 | 0.100 |
Why?
|
| Antitubercular Agents | 1 | 2012 | 61 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2042 | 0.090 |
Why?
|
| Models, Economic | 1 | 2012 | 62 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 2 | 2024 | 235 | 0.090 |
Why?
|
| Decision Making | 1 | 2016 | 695 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 199 | 0.080 |
Why?
|
| Itraconazole | 1 | 2009 | 12 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2009 | 30 | 0.080 |
Why?
|
| Physicians | 1 | 2016 | 707 | 0.070 |
Why?
|
| China | 1 | 2009 | 264 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2020 | 74 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1166 | 0.060 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 593 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2885 | 0.060 |
Why?
|
| Monte Carlo Method | 2 | 2017 | 191 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2017 | 686 | 0.060 |
Why?
|
| Hospitalization | 2 | 2021 | 946 | 0.060 |
Why?
|
| Bleomycin | 1 | 2024 | 101 | 0.050 |
Why?
|
| Gender Identity | 1 | 2025 | 60 | 0.050 |
Why?
|
| Housing | 1 | 2024 | 50 | 0.050 |
Why?
|
| Transportation | 1 | 2024 | 20 | 0.050 |
Why?
|
| Adolescent | 4 | 2019 | 9878 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2024 | 76 | 0.050 |
Why?
|
| Needle-Exchange Programs | 1 | 2023 | 19 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 599 | 0.050 |
Why?
|
| Data Collection | 1 | 2023 | 381 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2024 | 1018 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2024 | 776 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 30 | 0.040 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 24 | 0.040 |
Why?
|
| Jurisprudence | 1 | 2021 | 26 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2021 | 65 | 0.040 |
Why?
|
| Community Networks | 1 | 2021 | 32 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2020 | 53 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 12 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 17 | 0.040 |
Why?
|
| Criminal Law | 1 | 2020 | 14 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2020 | 25 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 43 | 0.040 |
Why?
|
| Patient Selection | 1 | 2024 | 708 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 74 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2019 | 28 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2023 | 1191 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 105 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 376 | 0.030 |
Why?
|
| Mental Health | 1 | 2019 | 202 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 936 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 348 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 640 | 0.030 |
Why?
|
| Leishmania | 1 | 2017 | 7 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 66 | 0.030 |
Why?
|
| Social Isolation | 1 | 2017 | 71 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2017 | 86 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 162 | 0.030 |
Why?
|
| Stereotyping | 1 | 2016 | 17 | 0.030 |
Why?
|
| Health Communication | 1 | 2016 | 14 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 41 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 54 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 79 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 710 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 386 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 185 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 137 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 255 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2015 | 194 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 209 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 157 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1231 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 276 | 0.020 |
Why?
|
| Nigeria | 1 | 2013 | 162 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 164 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3922 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1982 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 857 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 636 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1561 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 890 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 12525 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 1883 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 905 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3969 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2860 | 0.020 |
Why?
|
| Child | 1 | 2017 | 7621 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 28901 | 0.010 |
Why?
|